Rhelion Life Sciences Reports First Quarter 2027 Results

Toronto, Ontario--(Newsfile Corp. - August 31, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to report its financial and operational results for the three months ended June 30, 2026 ("Q1 2027"), capping a transitional quarter which culminated in the acquisition of Filament Health Corp. ("Filament"). All figures are reported in Canadian dollars. The full set of the Company's unaudited condensed interim consolidated financial statements and accompanying management's discussions and analysis can be accessed by visiting the Company's website at www.Rhelion.com and its profile page on SEDAR+ at www.sedarplus.ca.

Q1 2027 Marks the Beginning of Rhelion's New Life Sciences Platform